Location History:
- Stockholm, SE (1998 - 2020)
- Årsta, SE (2002 - 2021)
- Arsta, SE (2015 - 2023)
Company Filing History:
14 out of 52 
3 out of 55 
2 out of 60 
Years Active: 1998-2024
Title: Innovations of Stefan Winge in Glycosylated Proteins
Introduction
Stefan Winge, located in Arsta, Sweden, is an accomplished inventor with a remarkable portfolio of 20 patents. His work primarily focuses on the development of glycosylated proteins that enhance pharmacokinetics and immune responses, making significant contributions to the field of biotechnology and pharmaceuticals.
Latest Patents
One of Winge's latest patents revolves around "Glycosylated VWF fusion proteins with improved pharmacokinetics." This invention involves a fusion protein that consists of a main protein similar to a mammalian protein and extension peptides containing O-glycosylated amino acids. Notably, this fusion protein shows an increased half-life compared to the main protein, making it particularly valuable for enhancing the efficacy of binding partners, such as FVIII. Additionally, the patent encompasses the complex formed by the fusion protein, the encoding polynucleotide, as well as the vector and host cell containing the said polynucleotide.
Another noteworthy invention pertains to "Polypeptides modulating SIGLEC dependent immune responses." This innovation features a glycosylated polypeptide with an amino acid sequence that aligns with fragments of mammalian proteins. The polypeptide is designed to contain sialylated O-glycans, demonstrating enhanced binding affinity to several SIGLECs (SIG-5, SIG-7, SIG-8, and SIG-9). The patent further describes compositions combining two polypeptides, one of which enhances the binding affinity to SIGLECs significantly.
Career Highlights
Throughout his career, Stefan Winge has made significant strides working with renowned companies such as Octapharma AG and Biovitrum AB. His innovative spirit and dedication to research have placed him at the forefront of biotechnology.
Collaborations
Winge has collaborated with talented professionals in the field, including Gustav Gilljam and Christoph Kannicht. These partnerships have allowed him to exchange ideas and drive forward groundbreaking developments in glycosylated proteins and their therapeutic applications.
Conclusion
Stefan Winge's innovative contributions to the field of glycosylated proteins not only enhance the understanding of pharmacokinetics but also provide critical advancements in immune response modulation. His patents signify an ongoing commitment to improving therapeutic outcomes and reinforcing the significance of innovative research in biotechnology.